ReviewPharmaceutics2019
Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities.
Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Low Luteal Serum Progesterone Levels Are Associated With Lower Ongoing Pregnancy and Live Birth Rates in ART: Systematic Review and Meta-Analyses.Frontiers in endocrinology · 2022Pooled it
- Ovarian Folliculogenesis and Uterine Endometrial Receptivity after Intermittent Vaginal Injection of Recombinant Human Follicle-Stimulating Hormone in Infertile Women Receiving In Vitro Fertilization and in Immature Female Rats.International journal of molecular sciences · 2021Trial
- Recovery ofNutrients · 2020Trial
- Obstetric Pharmacomicrobiomics.Clinical pharmacology and therapeutics · 2026Review
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- The Vaginal Microbiome: Associations with Vaginal pH, Menopause and Metabolic Parameters.Microorganisms · 2025Article
- In Vitro Bactericidal Activity of a Neomycin-Polymyxin B-Nystatin Combination Compared to Metronidazole and Clindamycin Against the Main Bacteria Involved in Bacterial Vaginosis and Aerobic Vaginitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Recent Advances in Studying In Vitro Drug Permeation Across Mucosal Membranes.Pharmaceutics · 2025Review
- Review
- Retrospective Investigator-Initiated Trial on Tocopherol Acetate Vaginal Administration in Pre-and Postmenopausal Women.Diseases (Basel, Switzerland) · 2024Article
- Enterococcal-host interactions in the gastrointestinal tract and beyond.FEMS microbes · 2024Review
- Prevalence ofIranian journal of microbiology · 2023Article
- New Possibilities for Hormonal Vaginal Treatment in Menopausal Women.Journal of clinical medicine · 2023Review
- Possible Therapeutic Mechanisms and Future Perspectives of Vaginal Microbiota Transplantation.Microorganisms · 2023Review
- Article
- The interplay between human papillomavirus and vaginal microbiota in cervical cancer development.Virology journal · 2023Review
- Development of Mucoadhesive Electrospun Scaffolds for Intravaginal Delivery ofPharmaceutics · 2023Article
- Vaginal Sheets withGels (Basel, Switzerland) · 2023Article
- Vaginal Nanoformulations for the Management of Preterm Birth.Pharmaceutics · 2022Review
- Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vaginal drug delivery represents an attractive alternative to achieve local and systemic effects due to the high contact surface exposed, the mucoadhesion of the epithelium, and the high innervation that facilitates the absorption of drugs into the bloodstream. However, despite the confinement of the vaginal cavity, it is an organ with a highly variable microenvironment. Mechanical alterations such as coitus, or chemical changes such as pH and viscosity, modify the release of drugs. In addition, changes in vaginal microbiota can influence the entire vaginal microenvironment, thus determining the disposition of drugs in the vaginal cavity and decreasing their therapeutic efficacy. Therefore, the influence of microorganisms on vaginal homeostasis can change the pre-established scenario for the application of drugs. This review aims to provide an explanation of normal vaginal microbiota, the factors that modify it, its involvement in the administration of drugs, and new proposals for the design of novel pharmaceutical dosage forms. Finally, challenges and opportunities directed toward the conception of new effective formulations are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.